TAK, US8740602052

Takeda presents oncology data and Takeda stock costs EUR 16.55

Published on 10/09/2026 at 11:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Core revenue fell 0.5 percent at constant exchange rates in the first quarter of fiscal 2026. Takeda stock costs EUR 16.55 on October 9, 2026 after EUR 16.55.

Key points in brief

Takeda presented late-stage oncology research for the October 23, 2026 ESMO session, including Phase 3 data.
First-quarter fiscal 2026 core revenue reached JPY 1.22 trillion, down 0.5 percent at constant exchange rates.
Takeda stock was unchanged at EUR 16.55 at Lang & Schwarz on October 9, 2026, versus a EUR 16.55 prior close.
Analysts raised Takeda's price target to JPY 5,800 from JPY 5,600 on September 19, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda (ISIN US8740602052) had announced oncology data for the October 23, 2026 ESMO session, while Takeda stock was unchanged at EUR 16.55 at Lang & Schwarz on October 9, 2026. The prior close was EUR 16.55, and the company is preparing several late-stage studies for presentation in Madrid.

Oncology data arrives October 23

According to Takeda on September 22, 2026, the company planned a late-breaking presentation of Phase 3 G-HOPE-001 data for arcotatug tavatecan in previously treated advanced gastric or gastroesophageal junction cancer. The session is scheduled for October 23, 2026, from 1:30 p.m. to 3:00 p.m. CEST.

The release also identified two TAK-928 presentations involving immunotherapy-resistant and previously untreated non-small cell lung cancer. Takeda said the investigational compounds arcotatug tavatecan and TAK-928 had not received approval from the U.S. Food and Drug Administration or another regulatory authority as of September 22, 2026.

What do the results mean for growth?

The latest operating figures show why pipeline execution matters. ScanX reported on September 17, 2026 that core revenue reached JPY 1.22 trillion in the first quarter of fiscal 2026, down 0.5 percent at constant exchange rates. On an actual foreign-exchange basis, revenue rose 10.2 percent, while reported operating profit stood at JPY 201.4 billion.

That gap between a 10.2 percent reported increase and a 0.5 percent constant-rate decline makes currency a material part of the first-quarter comparison. New launches contributed 4 percent of revenue and grew 22.6 percent at constant exchange rates, according to ScanX.

Three dated signals for Takeda

On September 17, 2026, ScanX reported first-quarter core revenue of JPY 1.22 trillion and a 0.5 percent constant-rate decline. On September 19, 2026, Simply Wall St reported that analysts raised the target to JPY 5,800 from JPY 5,600. On September 22, 2026, Takeda announced the ESMO oncology program with the October 23 Phase 3 data session.

Next dates carry the catalyst

The next two dated events are the ESMO oncology presentation on October 23, 2026, and Takeda's second-quarter fiscal 2026 results on October 29, 2026. MarketBeat lists the October 29 report before the market opens, with consensus revenue of USD 7.32 billion.

Stock holds at EUR 16.55

Takeda stock was trading at EUR 16.55 at Lang & Schwarz on October 9, 2026 at 11:47 a.m. CEST, unchanged versus the EUR 16.55 prior close. The finance quote for the NYSE-listed ADR showed a market capitalization of USD 58.9 billion, a 52-week range of USD 12.99 to USD 19.10 and a last price of USD 18.52 on October 8, 2026 at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Takeda stock.